Trial Profile
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2014
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Jun 2008 Trial centres updated from nct (last updated 11-6-08).
- 30 May 2008 Results presented at the 44th Annual Meeting of the American Society of Clinical Oncology.
- 20 Dec 2007 Status changed from in progress to completed according to an AstraZeneca media release.